Skip to content
value.today

ViewRay: peers

Change the peers

ViewRay beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

ViewRay, Guided Therapeutics Inc., ENvue Medical, Inc., Escalon Medical Corp., Nu-Med Plus Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

ViewRay, Nuwellis, Inc., Guided Therapeutics Inc., Nexalin Technology, Inc., ENvue Medical, Inc., Escalon Medical Corp., Nu-Med Plus Inc., NeuroOne Medical Technologies Corporation side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureViewRaybase
VRAY · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nuwellis, Inc.
NUWE · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Guided Therapeutics Inc.
GTHP · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nexalin Technology, Inc.
NXL · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
ENvue Medical, Inc.
FEED · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Escalon Medical Corp.
ESMC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nu-Med Plus Inc.
NUMD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
NeuroOne Medical Technologies Corporation
NMTC · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$4 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one3rd of 8$3 MOct 30, 2026 · Market data4th of 8$7 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one2nd of 8$2 MOct 27, 2026 · Market data5th of 8$2 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8$2 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one6th of 8$2 Mlast known, Jan 7, 2022 · Market dataLast known value: no current one6th of 8$8 MOct 30, 2026 · Market data1st of 8$3 M8 ranked
Revenue (Better neither way: ranked highest first)——$8 MFY2025 · SEC3rd of 6$1 MFY2025 · SEC5th of 6$0 MFY2025 · SEC6th of 6$3 MFY2025 · SEC4th of 6$13 MFY2026 · SEC1st of 6——$9 MFY2025 · SEC2nd of 6$5 M6 ranked
Net income (Higher is better)——$-18 MFY2025 · SEC6th of 7$-3 MFY2025 · SEC3rd of 7$-8 MFY2025 · SEC5th of 7$-18 MFY2025 · SEC7th of 7$4 MFY2026 · SEC1st of 7$-0 MFY2025 · SEC2nd of 7$-4 MFY2025 · SEC4th of 7$-4 M7 ranked
Employees (Better neither way: ranked highest first)267As on 2021 · Profile1st of 538December 31, 2025 · Profile3rd of 5——8December 31, 2025 · Profile5th of 5——40June 30, 2026 · Profile2nd of 5——18September 30, 2025 · Profile4th of 5385 ranked
Growth
Revenue growth (Higher is better)————-5.4%FY2025 · SEC4th of 417th17th————————-0.4%FY2025 · SEC3rd of 425th28th+5.7%FY2026 · SEC2nd of 439th48th————+163.8%FY2025 · SEC1st of 495th98th+2.7%4 ranked
Revenue growth, 3 years a year (Higher is better)————-1.1%FY2025 · SEC4th of 424th29th————————+50.4%FY2025 · SEC2nd of 488th96th+1.5%FY2026 · SEC3rd of 431st38th————+276.9%FY2025 · SEC1st of 4100th100th+25.9%4 ranked
Margins and returns
Gross margin (Higher is better)————61.9%FY2025 · SEC1st of 455th76th————————5.9%FY2025 · SEC4th of 44th5th43.7%FY2026 · SEC3rd of 428th56th————56.5%FY2025 · SEC2nd of 447th70th50.1%4 ranked
Operating margin (Higher is better)————-134.3%FY2025 · SEC3rd of 420th9th————————-897.6%FY2025 · SEC4th of 41st0th0.4%FY2026 · SEC1st of 458th41st————-46.5%FY2025 · SEC2nd of 432nd15th-90.4%4 ranked
Net margin (Higher is better)————-211.8%FY2025 · SEC3rd of 414th5th————————-712.9%FY2025 · SEC4th of 43rd1st31.5%FY2026 · SEC1st of 495th95th————-39.7%FY2025 · SEC2nd of 434th16th-125.8%4 ranked
Free cash flow margin (Higher is better)————-131.8%FY2025 · SEC3rd of 418th7th————————-369.8%FY2025 · SEC4th of 49th2nd-3.1%FY2026 · SEC1st of 447th28th————-32.1%FY2025 · SEC2nd of 432nd15th-81.9%4 ranked
Return on equity (Higher is better)————-382.9%FY2025 · SEC5th of 53rd1st————-221.3%FY2025 · SEC4th of 59th4th-106.5%FY2025 · SEC3rd of 523rd10th102.2%FY2026 · SEC1st of 599th99th————-91.5%FY2025 · SEC2nd of 527th11th-106.5%5 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————0.3×price Oct 30, 2026 · Market data3rd of 35th10th————7.8×price Oct 27, 2026 · Market data1st of 368th86th————————————0.9×price Oct 30, 2026 · Market data2nd of 315th27th0.9×3 ranked
Price to book (Better neither way: ranked highest first)————1.2×price Oct 30, 2026 · Market data1st of 322nd26th————0.6×price Oct 27, 2026 · Market data3rd of 38th8th————————————1.2×price Oct 30, 2026 · Market data1st of 322nd26th1.2×3 ranked
Free cash flow yield (Higher is better)————————————————————————————-34.6%price Oct 30, 2026 · Market dataonly one with it24th10th-34.6%—
Financial strength
Interest cover (Higher is better)————————-3.8×FY2025 · SEC2nd of 359th33rd————————5.0×FY2026 · SEC1st of 386th74th-5.0×FY2025 · SEC3rd of 355th30th————-3.8×3 ranked
Scorecard
Scorecard (Higher is better)——4 of 18FY2025 · Scorecard5th of 70 of 8FY2025 · Scorecard7th of 72 of 12FY2025 · Scorecard6th of 73 of 13FY2025 · Scorecard4th of 78 of 15FY2026 · Scorecard1st of 73 of 9FY2025 · Scorecard3rd of 78 of 19FY2025 · Scorecard2nd of 723% passed7 ranked
Valuation checks (Higher is better)——2 of 4FY2025 · Scorecard1st of 3——1 of 4FY2025 · Scorecard3rd of 3——————2 of 5FY2025 · Scorecard2nd of 340% passed3 ranked
Growth checks (Higher is better)——0 of 6FY2025 · Scorecard5th of 70 of 2FY2025 · Scorecard5th of 70 of 1FY2025 · Scorecard5th of 72 of 6FY2025 · Scorecard4th of 74 of 6FY2026 · Scorecard2nd of 71 of 2FY2025 · Scorecard3rd of 74 of 5FY2025 · Scorecard1st of 733% passed7 ranked
Profitability checks (Higher is better)——1 of 5FY2025 · Scorecard2nd of 70 of 2FY2025 · Scorecard4th of 70 of 3FY2025 · Scorecard4th of 70 of 5FY2025 · Scorecard4th of 73 of 5FY2026 · Scorecard1st of 70 of 2FY2025 · Scorecard4th of 71 of 5FY2025 · Scorecard2nd of 70% passed7 ranked
Financial health checks (Higher is better)——1 of 3FY2025 · Scorecard2nd of 70 of 3FY2025 · Scorecard7th of 71 of 3FY2025 · Scorecard2nd of 71 of 2FY2025 · Scorecard1st of 71 of 3FY2026 · Scorecard2nd of 71 of 4FY2025 · Scorecard6th of 71 of 3FY2025 · Scorecard2nd of 733% passed7 ranked
Shareholder returns checks (Higher is better)————0 of 1FY2025 · Scorecard2nd of 50 of 1FY2025 · Scorecard2nd of 5——0 of 1FY2026 · Scorecard2nd of 51 of 1FY2025 · Scorecard1st of 50 of 1FY2025 · Scorecard2nd of 50% passed5 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——53.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3——0.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3——————18.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 318.3%3 ranked
Institutions holding (Better neither way: ranked highest first)——112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 3——92026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 3——————222026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 3113 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——————————————+23.8 pp2026-Q2 against 2026-Q1 · 13Fonly one with it+23.8 pp—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = ViewRay: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nuwellis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Guided Therapeutics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nexalin Technology, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ENvue Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Escalon Medical Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nu-Med Plus Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; NeuroOne Medical Technologies Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
ViewRay———
Nuwellis, Inc.-134.3%FY2025
20th percentile in Healthcaremedian -7.7%, 674 companies
9th percentile in USAmedian 3.5%, 2,594 companies
Guided Therapeutics Inc.———
Nexalin Technology, Inc.———
ENvue Medical, Inc.-897.6%FY2025
1st percentile in Healthcaremedian -7.7%, 674 companies
0th percentile in USAmedian 3.5%, 2,594 companies
Escalon Medical Corp.0.4%FY2026
58th percentile in Healthcaremedian -7.7%, 674 companies
41st percentile in USAmedian 3.5%, 2,594 companies
Nu-Med Plus Inc.———
NeuroOne Medical Technologies Corporation-46.5%FY2025
32nd percentile in Healthcaremedian -7.7%, 674 companies
15th percentile in USAmedian 3.5%, 2,594 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$6 M$13 M$19 M$26 M20112013201520172019202120232025Nuwellis, Inc. $8 MGuided Therapeutics Inc. $1 MNexalin Technology, Inc. $0 MENvue Medical, Inc. $3 MEscalon Medical Corp. $13 MNeuroOne Medical Technologies Corporation $9 M

Rank in the group

1st2nd3rd4th5th6th20122013201420152016201720182019202020212022202320242025Nuwellis, Inc.: 3rd of 3 in 2013Nuwellis, Inc.: 3rd of 4 in 2015Nuwellis, Inc.: 2nd of 3 in 2016Nuwellis, Inc.: 2nd of 4 in 2017Nuwellis, Inc.: 2nd of 4 in 2018Nuwellis, Inc.: 2nd of 4 in 2019Nuwellis, Inc.: 2nd of 4 in 2020Nuwellis, Inc.: 2nd of 6 in 2021Nuwellis, Inc.: 2nd of 4 in 2022Nuwellis, Inc.: 2nd of 5 in 2023Nuwellis, Inc.: 2nd of 6 in 2024Nuwellis, Inc.: 3rd of 6 in 2025Nuwellis, Inc.Guided Therapeutics Inc.: 2nd of 2 in 2012Guided Therapeutics Inc.: 2nd of 3 in 2013Guided Therapeutics Inc.: 3rd of 3 in 2014Guided Therapeutics Inc.: 4th of 4 in 2015Guided Therapeutics Inc.: 3rd of 4 in 2017Guided Therapeutics Inc.: 4th of 4 in 2018Guided Therapeutics Inc.: 4th of 4 in 2019Guided Therapeutics Inc.: 4th of 4 in 2020Guided Therapeutics Inc.: 6th of 6 in 2021Guided Therapeutics Inc.: 6th of 6 in 2024Guided Therapeutics Inc.: 5th of 6 in 2025Guided Therapeutics Inc.Nexalin Technology, Inc.: 5th of 6 in 2021Nexalin Technology, Inc.: 5th of 5 in 2023Nexalin Technology, Inc.: 5th of 6 in 2024Nexalin Technology, Inc.: 6th of 6 in 2025Nexalin Technology, Inc.ENvue Medical, Inc.: 2nd of 3 in 2014ENvue Medical, Inc.: 2nd of 4 in 2015ENvue Medical, Inc.: 3rd of 3 in 2016ENvue Medical, Inc.: 3rd of 4 in 2017ENvue Medical, Inc.: 3rd of 4 in 2018ENvue Medical, Inc.: 3rd of 4 in 2019ENvue Medical, Inc.: 3rd of 4 in 2020ENvue Medical, Inc.: 3rd of 6 in 2021ENvue Medical, Inc.: 3rd of 4 in 2022ENvue Medical, Inc.: 3rd of 5 in 2023ENvue Medical, Inc.: 4th of 6 in 2024ENvue Medical, Inc.: 4th of 6 in 2025ENvue Medical, Inc.Escalon Medical Corp.: 1st of 2 in 2012Escalon Medical Corp.: 1st of 3 in 2013Escalon Medical Corp.: 1st of 3 in 2014Escalon Medical Corp.: 1st of 4 in 2015Escalon Medical Corp.: 1st of 3 in 2016Escalon Medical Corp.: 1st of 4 in 2017Escalon Medical Corp.: 1st of 4 in 2018Escalon Medical Corp.: 1st of 4 in 2019Escalon Medical Corp.: 1st of 4 in 2020Escalon Medical Corp.: 1st of 6 in 2021Escalon Medical Corp.: 1st of 4 in 2022Escalon Medical Corp.: 1st of 5 in 2023Escalon Medical Corp.: 1st of 6 in 2024Escalon Medical Corp.: 1st of 6 in 2025Escalon Medical Corp.NeuroOne Medical Technologies Corporation: 4th of 6 in 2021NeuroOne Medical Technologies Corporation: 4th of 4 in 2022NeuroOne Medical Technologies Corporation: 4th of 5 in 2023NeuroOne Medical Technologies Corporation: 3rd of 6 in 2024NeuroOne Medical Technologies Corporation: 2nd of 6 in 2025NeuroOne Medical Technolog
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearViewRayNuwellis, Inc.Guided Therapeutics Inc.Nexalin Technology, Inc.ENvue Medical, Inc.Escalon Medical Corp.Nu-Med Plus Inc.NeuroOne Medical Technologies Corporation
2026—————$13 MSEC——
2025—$8 MSEC3rd$1 MSEC5th$0 MSEC6th$3 MSEC4th$12 MSEC1st—$9 MSEC2nd
2024—$9 MSEC2nd$0 MSEC6th$0 MSEC5th$3 MSEC4th$12 MSEC1st—$3 MSEC3rd
2023—$9 MSEC2nd—$0 MSEC5th$2 MSEC3rd$12 MSEC1st—$2 MSEC4th
2022—$9 MSEC2nd——$1 MSEC3rd$11 MSEC1st—$0 MSEC4th
2021—$8 MSEC2nd$0 MSEC6th$0 MSEC5th$2 MSEC3rd$10 MSEC1st—$0 MSEC4th
2020—$7 MSEC2nd$0 MSEC4th—$1 MSEC3rd$9 MSEC1st——
2019—$6 MSEC2nd$0 MSEC4th—$1 MSEC3rd$10 MSEC1st——
2018—$5 MSEC2nd$0 MSEC4th—$0 MSEC3rd$11 MSEC1st——
2017—$4 MSEC2nd$0 MSEC3rd—$0 MSEC3rd$11 MSEC1st——
2016—$1 MSEC2nd——$0 MSEC3rd$12 MSEC1st——
2015—$0 MSEC3rd$0 MSEC4th—$0 MSEC2nd$13 MSEC1st——

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of ViewRay#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Nuwellis, Inc.NUWE · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $3 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $3 M (Oct 30, 2026) · revenue $8 M (year to December 2025)
    98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)
    In the group
  • Guided Therapeutics Inc.GTHP · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $7 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $7 M (last known, Jul 30, 2023) · revenue $1 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Nexalin Technology, Inc.NXL · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2 M (Oct 27, 2026) · revenue $0 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • ENvue Medical, Inc.FEED · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2 M (last known, Jan 5, 2024) · revenue $3 M (year to December 2025)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Escalon Medical Corp.ESMC · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2 M (last known, Jul 30, 2023) · revenue $13 M (year to June 2026)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • Nu-Med Plus Inc.NUMD · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $2 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $2 M (last known, Jan 7, 2022)
    96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)
    In the group
  • NeuroOne Medical Technologies CorporationNMTC · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $8 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $8 M (Oct 30, 2026) · revenue $9 M (year to September 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • Viveve MedicalVIVE · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $4 M market cap against $4 M · Same country: USA
    Market cap $4 M (last known, Dec 25, 2022)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    + Add
  • Micron SolutionsMICR · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $4 M market cap against $4 M · Same country: USA
    Market cap $4 M (last known, Jul 30, 2023)
    95 of 100 (industry or sector 50 + size 30 + country 15)
    + Add
  • Aethlon Medical, Inc.AEMD · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $9 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $9 M (Oct 30, 2026)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • Odyssey Group InternationalODYY · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $9 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $9 M (last known, Jul 30, 2023)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    + Add
  • ADM Tronics Unlimited Inc.ADMT · 🇺🇸 USA
    Same industry: Medical Devices · Similar size: $10 M market cap against $4 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $10 M (last known, Jul 30, 2023) · revenue $3 M (year to March 2026)
    94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.